RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Because CX717 IV would need to go through extended tox testing before going into human studies. It would take about as much money (and more time) to get CX717 IV ready for Phase I (never mind Phase II) as it will cost to do this SA POC study for CX-1739. They didn't have enough money to do both, so they went for SA--where there is infinitely more 'bang for the buck.'

As for clinical holds--I don't have a database of all holds, but they are not a 'kiss of death'.

I'm signing off for a day now--I have to leave for a meeting where I'll be on a panel being questioned about the future of neuro drug development by a group of BP neuroscientists and the like; pretty much all of whom are considerably smarter than I am. Assuming I survive that experience, I'll be back tomorrow and will look in, since the quality of discourse has improved considerably over the past 24 hours.

NeuroInvestment